HAFC
HANMI FINANCIAL CORP
$31.75
+1.54%
$945.1M
No data for this timeframe.
Vol
Market Cap$945.1M
Cap SizeSmall Cap
Analyst ConsensusBuy (60%)
Inst. Holders50 funds
Inst. Value$438.5M
Inst. Activity16 buys / 6 sells
Insider Activity0B / 2S
Insider Net $-$265.6K
SEC Reports8
Recent Activity
Jun 8, 2026
Insider
Kim Anthony I. sold 5,333 shares
Chief Banking Officer @ $30.73 ($163.9K)
May 27, 2026
Insider
Ball Christine P was granted 2,298 shares
Director
May 27, 2026
Insider
Medici Daniel John was granted 2,298 shares
Director
Apr 29, 2026
SEC
Hanmi Financial Corp filed a DEFA14A errata correcting the proxy statement for the 2026 annual meeting, specifically cla
DEFA14A — Impact 2/10
Apr 23, 2026
SEC
Hanmi Financial Corporation declared a quarterly cash dividend of $0.28 per share, payable on May 20, 2026, to sharehold
8-K — Impact 3/10
Apr 21, 2026
SEC
Hanmi Financial reported Q1 2026 earnings with $0.75 diluted EPS, beating consensus of $0.70 by 7.1%, driven by net inte
8-K — Impact 8/10
Inst.
CHARLES SCHWAB INVESTMENT MANAGEMENT — DOUBLED
960,547 shares ($25.3M)
Inst.
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP — ADD
413,571 shares ($10.9M)
Price Targets
$32.88
+3.5% upside
Hold
Current $31.75
Low $31.50
Median $32.50
High $35.00
4 analysts
$31.50
$35.00
Analyst Ratings
2Strong Buy
4Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 27, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Apr 9, 2026 | Keefe, Bruyette & Woods | MAINTAIN | Market Perform → Market Perform |
| Apr 2, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Feb 2, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Jan 29, 2026 | DA Davidson | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.77 | $0.76 — $0.78 | 54% YoY | 4 |
| Next Q | $0.81 | $0.80 — $0.82 | 11% YoY | 4 |
| Current FY | $3.16 | $3.13 — $3.18 | 26% YoY | 4 |
| Next FY | $3.42 | $3.35 — $3.50 | 8% YoY | 4 |
Latest Reports
NEUTRAL
DEFA14A
2/10
Hanmi Financial Corp filed a DEFA14A errata correcting the proxy statement for the 2026 annual meeting, specifically cla
Apr 29, 2026
NEUTRAL
8-K
3/10
Hanmi Financial Corporation declared a quarterly cash dividend of $0.28 per share, payable on May 20, 2026, to sharehold
Apr 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $115.7M | — |
| DIMENSIONAL FUND ADVISORS LP | $46.4M | — |
| STATE STREET CORP | $40.6M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $34.5M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $25.3M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | Kim Anthony | SELL | $163.9K |
| May 27, 2026 | Ball Christine | A | $0.00 |
| May 27, 2026 | Medici Daniel | A | $0.00 |
| May 27, 2026 | Williams Thomas | A | $0.00 |
| May 27, 2026 | Lee Gloria | A | $0.00 |
50 institutional holders with $438.5M total value (16,633,608 shares) as of 2026-Q1. Top holders: BlackRock,, DIMENSIONAL, STATE. Net buying activity: 16 institutions added/increased vs 6 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 4,388,598 | $115.7M | 26.4% | — |
| 2 | DIMENSIONAL FUND ADVISORS LP | 1,760,855 | $46.4M | 10.6% | — |
| 3 | STATE STREET CORP | 1,540,415 | $40.6M | 9.3% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1,307,548 | $34.5M | 7.9% | — |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 960,547 | $25.3M | 5.8% | DOUBLED +174.3% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 745,059 | $19.6M | 4.5% | — |
| 7 | GOLDMAN SACHS GROUP INC | 615,797 | $16.2M | 3.7% | — |
| 8 | HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | 489,546 | $12.9M | 2.9% | TRIM -27.1% |
| 9 | MORGAN STANLEY | 478,761 | $12.6M | 2.9% | — |
| 10 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 413,571 | $10.9M | 2.5% | ADD +26.9% |
| 11 | TWO SIGMA INVESTMENTS, LP | 348,647 | $9.2M | 2.1% | ADD +58.2% |
| 12 | AMERIPRISE FINANCIAL INC | 259,933 | $6.9M | 1.6% | — |
| 13 | Invesco Ltd. | 219,983 | $5.8M | 1.3% | TRIM -36.6% |
| 14 | FMR LLC | 215,903 | $5.7M | 1.3% | TRIM -62.2% |
| 15 | VANGUARD FIDUCIARY TRUST CO | 193,262 | $5.1M | 1.2% | — |
| 16 | RENAISSANCE TECHNOLOGIES LLC | 185,511 | $4.9M | 1.1% | TRIM -42.5% |
| 17 | LOOMIS SAYLES & CO L P | 184,634 | $4.9M | 1.1% | — |
| 18 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 151,677 | $4.0M | 0.9% | — |
| 19 | JUPITER ASSET MANAGEMENT LTD | 139,040 | $3.7M | 0.8% | — |
| 20 | FIRST TRUST ADVISORS LP | 136,457 | $3.6M | 0.8% | DOUBLED +240.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 350,173 | 960,547 | +174.3% | $25.3M | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | 325,916 | 413,571 | +26.9% | $10.9M | 2026-Q1 |
| Invesco Ltd. | TRIM | 347,094 | 219,983 | -36.6% | $5.8M | 2026-Q1 |
| FMR LLC | TRIM | 571,401 | 215,903 | -62.2% | $5.7M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 322,852 | 185,511 | -42.5% | $4.9M | 2026-Q1 |
| Trexquant Investment LP | ADD | 71,026 | 119,378 | +68.1% | $3.1M | 2026-Q1 |
| FRANKLIN RESOURCES INC | ADD | 48,600 | 75,752 | +55.9% | $2.0M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | TRIM | 120,026 | 69,986 | -41.7% | $1.8M | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 188,558 | 65,717 | -65.1% | $1.7M | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 16,296 | 50,903 | +212.4% | $1.3M | 2026-Q1 |
| Rafferty Asset Management, LLC | ADD | 19,308 | 32,705 | +69.4% | $862.1K | 2026-Q1 |
| Horizon Investments, LLC | ADD | 21,543 | 27,547 | +27.9% | $719.5K | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 18,624 | 24,449 | +31.3% | $644.5K | 2026-Q1 |
| Brevan Howard Capital Management LP | ADD | 12,785 | 23,118 | +80.8% | $609.4K | 2026-Q1 |
| State of Tennessee, Department of Treasury | NEAR_EXIT | 49,633 | 12,204 | -75.4% | $321.7K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 200 | 8,493 | +4146.5% | $223.9K | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 223 | 7,949 | +3464.6% | $209.5K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 562 | 2,811 | +400.2% | $74.1K | 2026-Q1 |
| FEDERATED HERMES, INC. | DOUBLED | 103 | 2,685 | +2506.8% | $70.8K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 744 | 1,185 | +59.3% | $31.2K | 2026-Q1 |
| ASSETMARK, INC | DOUBLED | 3 | 1,054 | +35033.3% | $27.8K | 2026-Q1 |
| Allworth Financial LP | ADD | 485 | 617 | +27.2% | $16.3K | 2026-Q1 |
| FMR LLC | NEAR_EXIT | 2,419,019 | 571,401 | -76.4% | $15.4M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 219,552 | 322,852 | +47.1% | $8.7M | 2025-Q4 |
| Point72 Asset Management, L.P. | DOUBLED | 14,174 | 188,558 | +1230.3% | $5.1M | 2025-Q4 |
15 unique insiders with 50 transactions. Net insider value: -$265.6K ($0.00 bought, $265.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Kim Anthony I. | Chief Banking Officer | SELL | 5,333 | $30.73 | $163.9K |
| May 27, 2026 | Ball Christine P | Director | AWARD | 2,298 | — | — |
| May 27, 2026 | Medici Daniel John | Director | AWARD | 2,298 | — | — |
| May 27, 2026 | Williams Thomas James | Director | AWARD | 2,298 | — | — |
| May 27, 2026 | Lee Gloria J | Director | AWARD | 2,298 | — | — |
| May 27, 2026 | Rosenblum David L | Director | AWARD | 2,298 | — | — |
| May 27, 2026 | Marasco James A | Director | AWARD | 2,298 | — | — |
| May 27, 2026 | Ahn John J | Director | AWARD | 2,298 | — | — |
| May 27, 2026 | Chung Harry | Director | AWARD | 2,298 | — | — |
| May 27, 2026 | Chu Christie K | Director | AWARD | 2,298 | — | — |
| Apr 28, 2026 | Fuhr Matthew | Chief Credit Officer | SELL | 3,300 | $30.83 | $101.7K |
| Apr 1, 2026 | Kim Anthony I. | Chief Banking Officer | TAX W/H | 563 | $26.60 | $15.0K |
| Apr 1, 2026 | Pangrazio Joseph | Chief Accounting Officer | TAX W/H | 148 | $26.60 | $3.9K |
| Apr 1, 2026 | LEE BONITA | President & CEO | TAX W/H | 3,769 | $26.60 | $100.3K |
| Apr 1, 2026 | Du Michael | Chief Risk Officer | TAX W/H | 360 | $26.60 | $9.6K |
| Apr 1, 2026 | Fuhr Matthew | Chief Credit Officer | TAX W/H | 492 | $26.60 | $13.1K |
| Apr 1, 2026 | SANTAROSA ROMOLO | Chief Financial Officer | TAX W/H | 916 | $26.60 | $24.4K |
| Mar 26, 2026 | SANTAROSA ROMOLO | Chief Financial Officer | TAX W/H | 553 | $26.33 | $14.6K |
| Mar 26, 2026 | SANTAROSA ROMOLO | Chief Financial Officer | AWARD | 7,623 | — | — |
| Mar 26, 2026 | Kim Anthony I. | Chief Banking Officer | TAX W/H | 339 | $26.33 | $8.9K |
| Mar 26, 2026 | Kim Anthony I. | Chief Banking Officer | AWARD | 4,455 | — | — |
| Mar 26, 2026 | Fuhr Matthew | Chief Credit Officer | TAX W/H | 297 | $26.33 | $7.8K |
| Mar 26, 2026 | Fuhr Matthew | Chief Credit Officer | AWARD | 3,697 | — | — |
| Mar 26, 2026 | Du Michael | Chief Risk Officer | TAX W/H | 169 | $26.33 | $4.4K |
| Mar 26, 2026 | Du Michael | Chief Risk Officer | AWARD | 2,367 | — | — |
| Mar 26, 2026 | Pangrazio Joseph | Chief Accounting Officer | TAX W/H | 65 | $26.33 | $1.7K |
| Mar 26, 2026 | LEE BONITA | President & CEO | TAX W/H | 2,391 | $26.33 | $63.0K |
| Mar 26, 2026 | LEE BONITA | President & CEO | AWARD | 22,260 | — | — |
| Mar 26, 2026 | Kim Anthony I. | Chief Banking Officer | TAX W/H | 339 | $26.33 | $8.9K |
| Mar 26, 2026 | Kim Anthony I. | Chief Banking Officer | AWARD | 4,455 | — | — |
| Mar 26, 2026 | LEE BONITA | President & CEO | TAX W/H | 2,391 | $26.33 | $63.0K |
| Mar 26, 2026 | LEE BONITA | President & CEO | AWARD | 22,260 | — | — |
| Mar 26, 2026 | Fuhr Matthew | Chief Credit Officer | TAX W/H | 297 | $26.33 | $7.8K |
| Mar 26, 2026 | Fuhr Matthew | Chief Credit Officer | AWARD | 3,697 | — | — |
| Mar 26, 2026 | SANTAROSA ROMOLO | Chief Financial Officer | TAX W/H | 553 | $26.33 | $14.6K |
| Mar 26, 2026 | SANTAROSA ROMOLO | Chief Financial Officer | AWARD | 7,623 | — | — |
| Mar 26, 2026 | Du Michael | Chief Risk Officer | TAX W/H | 169 | $26.33 | $4.4K |
| Mar 26, 2026 | Du Michael | Chief Risk Officer | AWARD | 2,367 | — | — |
| Mar 13, 2026 | Pangrazio Joseph | Chief Accounting Officer | AWARD | 483 | — | — |
| Mar 13, 2026 | SANTAROSA ROMOLO | Chief Financial Officer | AWARD | 4,913 | — | — |
| Mar 13, 2026 | LEE BONITA | President & CEO | AWARD | 18,832 | — | — |
| Mar 13, 2026 | Kim Anthony I. | Chief Banking Officer | AWARD | 3,159 | — | — |
| Mar 13, 2026 | Fuhr Matthew | Chief Credit Officer | AWARD | 2,761 | — | — |
| Mar 13, 2026 | Du Michael | Chief Risk Officer | AWARD | 1,596 | — | — |
| Mar 10, 2026 | LEE BONITA | President & CEO | TAX W/H | 1,669 | $25.55 | $42.6K |
| Mar 10, 2026 | Pangrazio Joseph | Chief Accounting Officer | TAX W/H | 150 | $25.55 | $3.8K |
| Mar 10, 2026 | Du Michael | Chief Risk Officer | TAX W/H | 205 | $25.55 | $5.2K |
| Mar 10, 2026 | Kim Anthony I. | Chief Banking Officer | TAX W/H | 385 | $25.55 | $9.8K |
| Mar 10, 2026 | Fuhr Matthew | Chief Credit Officer | TAX W/H | 319 | $25.55 | $8.2K |
| Mar 10, 2026 | SANTAROSA ROMOLO | Chief Financial Officer | TAX W/H | 656 | $25.55 | $16.8K |
8 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 6 neutral. Avg impact: 4.1/10.
NEUTRAL
DEFA14A
2/10
Hanmi Financial Corp filed a DEFA14A errata correcting the proxy statement for the 2026 annual meeti
Apr 29, 2026
NEUTRAL
8-K
3/10
Hanmi Financial Corporation declared a quarterly cash dividend of $0.28 per share, payable on May 20
Apr 23, 2026
BULLISH
8-K
8/10
Hanmi Financial reported Q1 2026 earnings with $0.75 diluted EPS, beating consensus of $0.70 by 7.1%
Apr 21, 2026
BULLISH
PRESS-RELEASE
7/10
Hanmi Bank (HAFC) reported Q1 2026 earnings with EPS of $0.75, beating the consensus estimate of $0.
Apr 21, 2026
NEUTRAL
DEFA14A
2/10
Hanmi Financial Corporation is holding its 2026 Annual Meeting of Stockholders on May 27, 2026. The
Apr 15, 2026
NEUTRAL
PRESS-RELEASE
3/10
Hanmi Bank announced a future earnings release date for Q1 2026, but did not report actual financial
Apr 7, 2026
NEUTRAL
S-3ASR
3/10
Hanmi Financial Corp filed an S-3ASR shelf registration to issue an unlimited amount of senior and s
Apr 3, 2026
NEUTRAL
8-K
5/10
Hanmi Financial Corporation filed an 8-K to disclose its fourth-quarter 2025 financial performance a
Feb 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (60% buy). Based on 10 analysts: 2 strong buy, 4 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$32.88 mean target
+3.5% upside
Hold (3.00)
$31.50 Low
$35.00 High
| Metric | Value |
|---|---|
| Current Price | $31.75 |
| Target Low | $31.50 |
| Target Mean | $32.88 |
| Target Median | $32.50 |
| Target High | $35.00 |
| # Analysts | 4 |
| Recommendation | Hold (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.77 | $0.76 | $0.78 | 54.0% | +0.0% | 4↑ 0↓ | $0.1B | 13.5% | 4 |
| Next Q 2026-09-30 |
$0.81 | $0.80 | $0.82 | 11.0% | +0.0% | 4↑ 0↓ | $0.1B | 7.2% | 4 |
| Current FY 2026-12-31 |
$3.16 | $3.13 | $3.18 | 25.9% | +0.0% | 4↑ 0↓ | $0.3B | 10.7% | 4 |
| Next FY 2027-12-31 |
$3.42 | $3.35 | $3.50 | 8.2% | +0.0% | 4↑ 0↓ | $0.3B | 7.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.770 | |
| 7d ago | $0.770 | |
| 30d ago | $0.770 | |
| 60d ago | $0.735 | +0.035 |
| 90d ago | $0.737 | +0.033 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 27, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Apr 9, 2026 | Keefe, Bruyette & Woods | MAINTAIN | Market Perform | Market Perform |
| Apr 2, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 2, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 29, 2026 | DA Davidson | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 4 | 0 | 0 | 60% | |
| May 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Apr 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Mar 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Feb 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Jan 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 21, 2026
earnings
Hanmi Reports 2026 First Quarter Results
<p align="justify">LOS ANGELES, April 21, 2026 (GLOBE NEWSWIRE) -- <strong>Hanmi Financial Corporation (NASDAQ: HAFC, or “Hanmi”)</strong>, the pare
Apr 21, 2026
earnings_calendar
HAFC Q1 2026 Earnings Scheduled — 2026-04-21
Apr 7, 2026
earnings
Hanmi Financial Corporation Announces First Quarter 2026 Earnings and Conference Call Date
<p>LOS ANGELES, April 07, 2026 (GLOBE NEWSWIRE) -- <strong>Hanmi Financial Corporation (Nasdaq: HAFC) (“Hanmi”)</strong>, the holding company for Ha
Apr 1, 2026
Clinical Trial
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: HM15211 (Phase 2)
Trial: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
Sponsor: Hanmi Pharmaceutical Company Limited
Phase
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: HM15211 (Phase 2)
Trial: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
Sponsor: Hanmi Pharmaceutical Company Limited
Phase
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: HM15211 (Phase 2)
Trial: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
Sponsor: Hanmi Pharmaceutical Company Limited
Phase
Mar 29, 2026
clinical_trial_readout
T-90d Trial Readout: HM15211 (Phase 2)
Trial: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
Sponsor: Hanmi Pharmaceutical Company Limited
Phase
Mar 5, 2026
other
Hanmi Issues 2025 Annual Shareholder Letter
Hanmi Bank issues 2025 Annual Shareholder Letter.